Carlos Corrêa-Netto

Dr. Carlos Corrêa-Netto

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Journal of Proteomics
Verified
Journal Article
Closed access
LGLarissa Gonçalves-Machado
Larissa Gonçalves-Machado
DPDavinia Pla
Davinia Pla
LSLibia Sanz
Libia Sanz
RJRoberta Jeane B. Jorge
Roberta Jeane B. Jorge
MLMoema Leitão-De-Araújo
Moema Leitão-De-Araújo
JCJuan Calvete
Juan Calvete

1 May 2019 in Journal of Proteomics
Verified
Journal Article
Closed access
LSLibia Sanz
Libia Sanz
SQSarai Quesada-Bernat
Sarai Quesada-Bernat
TRTyelli Ramos
Tyelli Ramos
LCLuciana Lyra Casais-e-Silva
Luciana Lyra Casais-e-Silva
CCCarlos Corrêa-Netto
Carlos Corrêa-Netto
JCJuan Calvete
Juan Calvete

12 May 2017 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
PDF file
RTRicardo Teixeira-Araújo
Ricardo Teixeira-Araújo
PCPatrícia Castanheira
Patrícia Castanheira
LBLeonora Brazil-Más
Leonora Brazil-Más
FPFrancisco Pontes
Francisco Pontes
MAMoema Leitão de Araújo
Moema Leitão de Araújo
CCCarlos Corrêa-Netto
Carlos Corrêa-Netto
Snakebite treatment requires administration of an appropriate antivenom that should contain antibodies capable of neutralizing the venom. To achieve this goal, antivenom production must start from a suitable immunization protocol and proper venom mixtures. In Brazil, antivenom against South American rattlesnake (Crotalus durissus terrificus) bites is produced by public institutions based on the guidelines defined by the regulatory agency of the Brazilian Ministry of Health, ANVISA. However, each institution uses its own mixture of rattlesnake venom antigens. Previous works have shown that crotamine, a toxin found in Crolatus durissus venom, shows marked individual and populational variation. In addition, serum produced from crotamine-negative venoms fails to recognize this molecule. In this work, we used an antivenomics approach to assess the cross-reactivity of crotalic antivenom manufactured by IVB towards crotamine-negative venom and a mixture of crotamine-negative/crotamine-positive venoms. We show that the venom mixture containing 20% crotamine and 57% crotoxin produced a strong immunogenic response in horses. Antivenom raised against this venom mixture reacted with most venom components including crotamine and crotoxin, in contrast to the antivenom raised against crotamine-negative venom. These results indicate that venomic databases and antivenomics analysis provide a useful approach for choosing the better venom mixture for antibody production and for the subsequent screening of antivenom cross-reactivity with relevant snake venom components.

26 December 2022 in Toxins
Verified
Journal Article
Open access
PDF file
CCCarlos Corrêa-Netto
Carlos Corrêa-Netto
MSMarcelo Abrahão Strauch
Marcelo Abrahão Strauch
Marcos Monteiro-MachadoMarcos Monteiro-Machado
Marcos Monteiro-Machado
RTRicardo Teixeira-Araújo
Ricardo Teixeira-Araújo
JFJuliana Guzzo Fonseca
Juliana Guzzo Fonseca
RUSSOLINA BENEDETA ZINGALIRUSSOLINA BENEDETA ZINGALI
RUSSOLINA BENEDETA ZINGALI
For over a century, polyclonal antibodies have been used to treat snakebite envenoming and are still considered by the WHO as the only scientifically validated treatment for snakebites. Nevertheless, moderate innovations have been introduced to this immunotherapy. New strategies and approaches to understanding how antibodies recognize and neutralize snake toxins represent a challenge for next-generation antivenoms. The neurotoxic activity of Micrurus venom is mainly due to two distinct protein families, three-finger toxins (3FTx) and phospholipases A2 (PLA2). Structural conservation among protein family members may represent an opportunity to generate neutralizing monoclonal antibodies (mAbs) against family-conserved epitopes. In this work, we sought to produce a set of monoclonal antibodies against the most toxic components of M. altirostris venom. To this end, the crude venom was fractionated, and its major toxic proteins were identified and used to generate a panel of five mAbs. The specificity of these mAbs was characterized by ELISA and antivenomics approaches. Two of the generated mAbs recognized PLA2 epitopes. They inhibited PLA2 catalytic activity and showed paraspecific neutralization against the myotoxicity from the lethal effect of Micrurus and Naja venoms’ PLA2s. Epitope conservation among venom PLA2 molecules suggests the possibility of generating pan-PLA2 neutralizing antibodies.

13 February 2025 in Toxins
Verified
Journal Article
Open access
PDF file
RTRicardo Teixeira-Araujo
Ricardo Teixeira-Araujo
MSMarisa Carvalho Suarez
Marisa Carvalho Suarez
CCCarlos Corrêa-Netto
Carlos Corrêa-Netto
LCLuis Eduardo Ribeiro da Cunha
Luis Eduardo Ribeiro da Cunha
DFDebora Foguel
Debora Foguel
RUSSOLINA BENEDETA ZINGALIRUSSOLINA BENEDETA ZINGALI
RUSSOLINA BENEDETA ZINGALI
High hydrostatic pressure (HHP) has been used for viral inactivation to facilitate vaccine development when immunogenicity is maintained or even increased. In this work, we used HHP to inactivate Bothrops jararacussu venom. Our protocol promotes the loss of or decrease in many biological activities in venom. Horses were immunized with pressurized venom, and in contrast to native venom, this procedure does not induce any damage to animals. Furthermore, the serum obtained with pressurized venom efficiently neutralized all biological activities of B. jararacussu venom. Antibody titrations were higher in serum produced with pressurized venom compared to that produced by native venom, and this antivenom was not only effective against the venom of B. jararacussu but against the venom of other species and genera. In conclusion, our data show a new technique for producing hyperimmune serum using venom inactivated by HHP, and this method is associated with a reduction in toxic effects in immunized animals and higher potency.